- Researchers have presented data from a Phase 2 study of Alexion Pharmaceuticals' (ALXN) targeted enzyme replacement therapy asfotase alfa in children and infants with hypophosphatasia.
- The study met its primary endpoint of improving skeletal mineralization from baseline.
- Improvement was observed as soon as 12 weeks and continued at 48 weeks, with 93% of those treated surviving the first four years of treatment.
- The drug has a Breakthrough Therapy designation. (PR)
Alexion's asfotase alfa meets primary endpoint in hypophosphatasia study
Sep 22 2013, 16:30 ET